

Anti-IL-12/IL-23 Antibody (Ustekinumab)

Introduction

Ustekinumab is a humanized monoclonal antibody that is primarily used to treat moderate to severe plaque psoriasis and psoriatic arthritis. It blocks the signaling pathways mediated by interleukin-12 (IL-12) and interleukin-23 (IL-23) by targeting and inhibiting the p40 subunits, thereby reducing inflammatory responses. Ustekinumab is derived from antibodies expressed in mammalian cells using recombinant DNA technology.

Product parameters

Alternative Names	Stelara
Target Accession	-
Target	IL-12/IL-23
CAS number	815610-63-0
Molecular Weight	-
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	1 mg/mL
Buffer System	100 mM Pro 20 mM Arg pH 5.0.
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

